Cabral-Marques, Otavio, Schimke, Lena F, Moll, Guido et al. · Autoimmunity reviews · 2025 · DOI
Scientists at an international conference discussed autoantibodies—immune proteins that can attack the body's own cells—that target structures called GPCRs found on many cells. These autoantibodies were once thought to be harmless side effects but are now recognized as active players in diseases including ME/CFS and long COVID. The conference brought together experts to share new ways of detecting these autoantibodies and ideas for using them as diagnostic tools and treatment targets.
This symposium report validates autoantibodies targeting GPCRs as active pathogenic factors in ME/CFS, moving beyond older views that dismissed them as epiphenomena. Recognition of RAB-GPCRs as disease modulators and potential biomarkers offers ME/CFS patients a concrete biological mechanism to study and potentially target therapeutically, supporting the legitimacy of immune-centered research in this condition.
This is a narrative evidence map and symposium summary, not a primary research study with quantitative data, so it does not prove causality between specific RAB-GPCRs and ME/CFS disease pathology. It does not establish diagnostic sensitivity/specificity, prognostic value, or treatment efficacy of RAB-GPCR-directed interventions in ME/CFS populations. The abstract does not detail sample sizes, control comparisons, or methodological rigor of the underlying studies discussed.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →